Nuchal Translucency Assessment at 11–13 Weeks Gestation
A nuchal translucency (NT) measurement of 2.6 mm at 11–13 weeks is more consistent with a normal finding than an enlarged NT if the measurement is below the gestational-age–adjusted 95th percentile and no structural anomalies are present. [1] Enlarged NT thresholds used for management pathways commonly include NT >3.5 mm for recommending chorionic villus sampling (CVS) or NT ≥3.0 mm as an ultrasound indication for further evaluation. [1], [2]
Normality Criteria for Nuchal Translucency
Normal NT on the 11–14 week scan is supported by documentation that NT thickness is <95th percentile for gestational age. [1] NT interpretation should include fetal crown–rump length (CRL) dating accuracy, since NT performance is tied to the 11 + 0 to 14 + 0 week scan window. [1]
Recommended Immediate Next Steps
A comprehensive first-trimester ultrasound assessment at 11–14 weeks should be performed that includes a structured evaluation rather than NT measurement alone. [1] An anatomy-focused scan should include assessment for major fetal defects, with planning for further prenatal evaluation when an enlarged NT or anomaly is identified. [1]
Screening and Testing Pathway After NT Measurement
For patients undergoing first-trimester aneuploidy screening, the ISUOG guidance supports a pathway with anomaly scan and NT assessment prior to cfDNA screening. [1] When NT is >3.5 mm or anomalies are present, CVS is recommended as the diagnostic next step in the ISUOG pathway. [1] When NT is not >3.5 mm and no anomalies are present, cfDNA screening is used in the ISUOG pathway (with reflex testing if cfDNA fails). [1] ACOG guidance states that when an enlarged NT or an anomaly is identified, genetic counseling and diagnostic testing should be offered. [3]
Timing of Follow-Up Ultrasound Evaluation
When an enlarged NT or an anomaly is identified, ACOG guidance recommends comprehensive ultrasound evaluation with detailed ultrasonography at 18–22 weeks to assess structural abnormalities. [3]
Common Pitfalls to Avoid
NT measurement should be interpreted in the context of gestational age and CRL-based dating, since management thresholds depend on the standardized 11–14 week assessment window and percentile interpretation. [1] Management should not be limited to NT alone, since structural anomalies may be present despite aneuploidy screening plans. [1]
Target Outcomes of Follow-Up
Follow-up should aim to establish whether there is aneuploidy risk requiring diagnostic testing versus residual risk managed with screening and targeted detailed anatomic evaluation. [1], [3]
Practical Summary for a 2.6 mm NT at 11–13 Weeks
A 2.6 mm NT at 11–13 weeks is typically treated as not meeting common “enlarged NT” thresholds used to trigger CVS, provided NT is <95th percentile and no fetal structural anomalies are identified. [1], [2] The next steps are confirmation of correct dating and measurement technique, completion of a detailed first-trimester anatomic evaluation, and then selection of cfDNA screening versus diagnostic testing based on whether NT is truly enlarged (including percentile assessment) and whether anomalies are present. [1] If NT is determined to be enlarged or if anomalies are found, genetic counseling, diagnostic testing, and a detailed 18–22 week anatomic ultrasound are recommended. [3]